Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95,022Revenue $M6,494Net Margin (%)21.8Z-Score7.3
Enterprise Value $M94,998EPS $1.7Operating Margin %28.5F-Score7
P/E(ttm))62.3Cash Flow Per Share $4.4Pre-tax Margin (%)25.0Higher ROA y-yN
Price/Book16.510-y EBITDA Growth Rate %0Quick Ratio6.1Cash flow > EarningsY
Price/Sales13.65-y EBITDA Growth Rate %22.2Current Ratio6.3Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %11.0ROA % (ttm)11.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)30.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M799ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGJohn Hussman 2014-09-30 Buy 0.2%$83.13 - $96.21
($90.29)
$ 118.9732%New holding, 25000 sh.25,000
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 118.9732%Add 77.12%232,137
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 118.9732%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 118.9732%Sold Out0
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 118.9757%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 118.9757%New holding, 63980 sh.63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 118.9757%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 118.9757%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 118.9757%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 118.9757%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 118.9750%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 118.9750%New holding, 1670 sh.3,340
CELGKen Fisher 2014-03-31 Add0.01%$69.65 - $85.97
($79.48)
$ 118.9750%Add 1591.8%74,642
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 118.9750%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 118.9750%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 118.9750%New holding, 6700 sh.13,400
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 118.9770%New holding, 1320 sh.2,640
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 118.9770%Add 29.5%20,940
CELGKen Fisher 2013-09-30 Reduce$60.13 - $77.31
($70.14)
$ 118.9770%Reduce -44.85%4,980
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 118.9770%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG John Hussman 2014-09-3025,00000.2New Buy
CELG Ken Fisher 2014-09-30232,1370.030.05+77.12%
CELG Mario Gabelli 2014-09-3025,76000.01+11.42%
CELG Ronald Muhlenkamp 2014-09-30146,9400.022.5+1.94%
CELG George Soros 2014-09-30000Sold Out
CELG Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.013.23view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.479.18view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.067.67view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.24.81view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.2712.35view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.2315.54view
HUGIN ROBERT Jsee remarks 2014-11-03Sell158,000$106.6816.13view
MARIO ERNESTDirector 2014-10-27Sell100,000$102.8520.46view
CASEY MICHAEL DDirector 2014-10-24Sell15,000$102.9420.35view
KAPLAN GILLADirector 2014-09-08Sell30,000$93.7332.18view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 

More From Our Partners
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015 - ZACKS

More From Other Websites
7:19 am Celgene receives positive chmp opinion for ABRAXANE for first-line treatment of patients... Jan 25 2015
Apple, Facebook Lead Top IBD 50 Earnings This Week Jan 24 2015
Cramer: Overwhelmed with earnings next week Jan 23 2015
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with... Jan 23 2015
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Jan 22 2015
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Jan 22 2015
The Zacks Analyst Blog Highlights: AbbVie, Gilead and Celgene - Press Releases Jan 22 2015
Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Jan 21 2015
Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Jan 21 2015
Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks Jan 21 2015
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Jan 20 2015
J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst Blog Jan 20 2015
Major U.S. benchmarks challenge last-ditch support Jan 20 2015
Cramer's Stop Trading: Biotech hangover Jan 20 2015
Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog Jan 19 2015
EU Oks new Celgene pill for psoriasis, psoriatic arthritis Jan 16 2015
EU Oks new Celgene pill for psoriasis, psoriatic arthritis Jan 16 2015
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients... Jan 16 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK